Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab vs. First-line DMT in newly diagnosed RMS
NCT04788615Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2021
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of ofatumumab in multiple sclerosis (MS), sponsored by Novartis. Started Jul 2021; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04788615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04788615.